Estradiol valerate, Norgestrel
Indications
Estradiol valerate, Norgestrel is used for:
ESTRADIOL
For the treatment of urogenital symptoms associated with post-menopausal atrophy of the vagina (such as dryness, burning, pruritus and dyspareunia) and/or the lower urinary tract (urinary urgency and dysuria)
NORGESTREL
Norgestrel in combination with ethinyl estradiol is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception
For the treatment of urogenital symptoms associated with post-menopausal atrophy of the vagina (such as dryness, burning, pruritus and dyspareunia) and/or the lower urinary tract (urinary urgency and dysuria)
NORGESTREL
Norgestrel in combination with ethinyl estradiol is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Estradiol valerate, Norgestrel :
Mechanism of Action
ESTRADIOL
Estradiol enters target cells freely (e. G. , female organs, breasts, hypothalamus, pituitary) and interacts with a target cell receptor. When the estrogen receptor has bound its ligand it can enter the nucleus of the target cell, and regulate gene transcription which leads to formation of messenger rna. The mrna interacts with ribosomes to produce specific proteins that express the effect of estradiol upon the target cell. Estrogens increase the hepatic synthesis of sex hormone binding globulin (shbg), thyroid-binding globulin (tbg), and other serum proteins and suppress follicle-stimulating hormone (fsh) from the anterior pituitary
NORGESTREL
Norgestrel (and more specifically the active stereoisomer levonorgestrel) binds to the progesterone and estrogen receptors within the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins like levonorgestrel will slow the frequency of release of gonadotropin releasing hormone (gnrh) from the hypothalamus and blunt the pre-ovulatory lh (luteinizing hormone) surge. Loss of the lh surge inhibits ovulation and thereby prevents pregnancy
Estradiol enters target cells freely (e. G. , female organs, breasts, hypothalamus, pituitary) and interacts with a target cell receptor. When the estrogen receptor has bound its ligand it can enter the nucleus of the target cell, and regulate gene transcription which leads to formation of messenger rna. The mrna interacts with ribosomes to produce specific proteins that express the effect of estradiol upon the target cell. Estrogens increase the hepatic synthesis of sex hormone binding globulin (shbg), thyroid-binding globulin (tbg), and other serum proteins and suppress follicle-stimulating hormone (fsh) from the anterior pituitary
NORGESTREL
Norgestrel (and more specifically the active stereoisomer levonorgestrel) binds to the progesterone and estrogen receptors within the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins like levonorgestrel will slow the frequency of release of gonadotropin releasing hormone (gnrh) from the hypothalamus and blunt the pre-ovulatory lh (luteinizing hormone) surge. Loss of the lh surge inhibits ovulation and thereby prevents pregnancy